Manhattan BioSolutions establishes new laboratory space at the JLabs JNJ Innovation incubator in New York City

by Mbio2018|Published November 1, 2018

Manhattan BioSolutions secures non-dilutive angel funding

Published June 1, 2022

Manhattan BioSolutions Enters into a Research Collaboration And License Option Agreement with Binghamton University for the New Linker-Payload Technology

https://www.accesswire.com/703518/Manhattan-BioSolutions-Enters-into-a-Research-Collaboration-And-License-Option-Agreement-with-Binghamton-University-for-the-New-Linker-Payload-Technology NEW YORK, NY / ACCESSWIRE / June 1, 2022 / Manhattan BioSolutions, Inc., an emerging biotechnology company developing new classes of therapeutic […]

Published March 23, 2022

Grant Award from the University at Buffalo Center for Advanced Technology in Big Data and Health Sciences

https://www.24-7pressrelease.com/press-release/489820/manhattan-biosolutions-announces-grant-award-from-the-university-at-buffalo-center-for-advanced-technology-in-big-data-and-health-sciences Research grant to support the development of novel monoclonal antibody and antibody-drug conjugate programs for the treatment of cancer NEW YORK, […]

Published August 12, 2022

Manhattan BioSolutions, Inc. Signs Commercial Evaluation License Agreements with the National Institutes of Health (NIH) for Use of Monoclonal Antibodies in Novel Antibody-Drug Conjugate (ADC) Oncology Programs

https://www.accesswire.com/709117/Manhattan-BioSolutions-Inc-Signs-Commercial-Evaluation-License-Agreements-with-the-National-Institutes-of-Health-NIH-for-Use-of-Monoclonal-Antibodies-in-Novel-Antibody-Drug-Conjugate-ADC-Oncology-Programs NEW YORK, NY / ACCESSWIRE / July 20, 2022 / Manhattan BioSolutions, Inc. today announced it has entered into two commercial evaluation […]